Clinical Trial: the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07692256) titled 'the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients' on June 04.

Brief Summary: the study to investigate the efficacy of empagiflozin in pediatric heart failure

Study Start Date: Dec. 01, 2025

Study Type: INTERVENTIONAL

Condition: Heart Failure

Intervention: DRUG: Empagliflozin (EMPA)

It's a randomized open-label two-arm prospective parallel study of 60 pediatric hospitalized patients.

experimental Group : 30 patients will receive empagliflozin for 90 days in addition to standard of care. empagliflozin will be administered at a starting dose 0.25-0.5 mg/kg/day (maximum 25 mg per day) enterally once dail...